DRMA

Dermata Therapeutics' stock has experienced significant volatility and decline over the past six months. Key events include a positive movement in December 2025, the announcement of the Tome skincare line in March 2026, the appointment of a new VP of Marketing, a corporate update and financial results report, and the acceptance of an Australian patent application in April 2026. Maxim Group maintained a Buy rating but cut the target price, Bigger Capital updated their Schedule 13G/A filing, and RBC Capital initiated coverage with an outperform rating and a price target of $40.00. Shares of Dermata Therapeutics underwent a 1-15 reverse stock split.